Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.

Abstract

e16588Background: A pooled analysis of treatment-naive Chinese pts enrolled in the phase 3 COMPARZ studies VEG108844 (randomized, open-label, global study) and VEG113078 (sub-study to VEG108844 con...